| DIRECT COMPETITOR COMPARISON | |
| LXRX | DGEN.PK | MRK | PFE | Industry | | Market Cap: | 277.61M | N/A | 77.79B | 152.11B | 100.26M | | Employees: | 347 | N/A | 55,200 | 81,800 | 65 | | Qtrly Rev Growth (yoy): | -71.60% | -76.60% | 1.80% | -2.90% | 19.70% | | Revenue (ttm): | 15.64M | 1.50M | 23.37B | 45.82B | 14.01M | | Gross Margin (ttm): | N/A | 68.55% | 76.36% | 86.61% | 65.68% | | EBITDA (ttm): | -82.37M | -388.00K | 7.81B | 21.31B | -12.30M | | Oper Margins (ttm): | -569.11% | -26.93% | 26.63% | 37.42% | -124.89% | | Net Income (ttm): | -76.19M | -471.00K | 8.05B | 8.09B | N/A | | EPS (ttm): | -0.556 | N/A | 3.808 | 1.204 | -0.32 | | P/E (ttm): | N/A | N/A | 9.68 | 15.66 | 15.91 | | PEG (5 yr expected): | N/A | N/A | 2.18 | 5.85 | 1.30 | | P/S (ttm): | 17.53 | N/A | 3.27 | 3.20 | 9.33 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.08 | 1.30% | 57.77B | 12.45 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 47.84 | 1.92% | 13.84B | 16.01 | | Genzyme Corp. | GENZ | 51.11 | 0.81% | 13.56B | 29.14 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.40 | 0.63% | 41.76B | 17.94 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 50.76 | 1.97% | 9.05B | 1035.92 | | Teva Pharmaceutical Industries Limited | TEVA | 53.38 | 1.12% | 47.03B | 48.84 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.55 | 1.24% | 3.99B | 19.36 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.89 | 0.51% | 2.95B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.23 | 2.01% | 5.57B | 111.84 | | Pfizer Inc. | PFE | 18.85 | 3.74% | 152.11B | 15.66 | | Johnson & Johnson | JNJ | 63.51 | 1.07% | 175.23B | 13.87 | | GlaxoSmithKline plc | GSK | 42.41 | 2.27% | 107.51B | 13.46 | | Sanofi-Aventis | SNY | 39.32 | 3.58% | 102.67B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 56.16 | 1.01% | 127.55B | 16.81 | | RHHBY.PK | 41.40 | 1.17% | N/A | N/A | | AstraZeneca plc | AZN | 45.74 | 2.03% | 66.32B | 9.18 | | Abbott Laboratories | ABT | 54.48 | -0.02% | 84.27B | 14.76 | | Bristol-Myers Squibb Co. | BMY | 24.65 | -2.61% | 48.83B | 12.75 |
|
| NEWS ON DIRECT COMPETITORS | |
|
|
|